Targeting acetylcholinesterase and butyrylcholinesterase in dementia

International Journal of Neuropsychopharmacology

Volumn 9, Issue 1, 2006, Pages 101-124

  Lane, Roger M ^a   Potkin, Steven G ^b,c   Enz, Albert ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Cholinergic; Disease progression

Indexed keywords

ACETYLCHOLINESTERASE; AMINO ACID; AMYLOID BETA PROTEIN; ANTIEMETIC AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; TAU PROTEIN;

ALLOSTERISM; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AUTONOMIC DYSFUNCTION; BRADYCARDIA; BRAIN BLOOD VESSEL; BRAIN FUNCTION; BRAIN NERVE CELL; CARDIOVASCULAR DISEASE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CHOLINESTERASE INHIBITION; CLINICAL FEATURE; CONTROLLED RELEASE FORMULATION; DISEASE COURSE; DOSE RESPONSE; DRUG CAPSULE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; EXTRAPYRAMIDAL SYNDROME; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLIA CELL; HEART RATE VARIABILITY; HUMAN; INSOMNIA; MOLECULAR BIOLOGY; MUSCLE CRAMP; NAUSEA AND VOMITING; NEUROANATOMY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RHINITIS; SLEEP DISORDER; TABLET FORMULATION; TRANSDERMAL PATCH; URINE INCONTINENCE; VIVID DREAM;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BUTYRYLCHOLINESTERASE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR CIRCULATION; CHOLINERGIC FIBERS; CHOLINESTERASE INHIBITORS; DEMENTIA; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; ISOENZYMES; NEUROGLIA; POLYMORPHISM, GENETIC;

EID: 30344485665     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705005833     Document Type: Review

References (225)

1. Adler G, Brassen S (2001). Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology 43, 273-276.
2. Adler G, Brassen S, Chwalek K, Dieter B, Teufel M (2004). Prediction of treatment response to rivastigmine in Alzheimer's dementia. Journal of Neurology, Neurosurgery and Psychiatry 75, 292-294.
3. Adler G, Brassen S, Jajcevic A (2003). EEG coherence in Alzheimer's dementia. Journal of Neural Transmission 110, 1051-1058.
4. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W (2001). APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 12, 69-77.
5. Albert ML (1978). Subcortical dementia. In: Katzman R, Terry RD, Bick KL (Eds.), Alzheimer's Disease: Senile Dementia and Related Disorders (pp. 173-180). New York: Raven Press.
6. Aleman A, Verhaar HJ, De Haan EH, De Vries WR, Samson MM, Drent ML, Van der Veen EA, Koppeschaar HP (1999). Insulin-like growth factor-I and cognitive function in healthy older men. Journal of Clinical Endocrinology and Metabolism 84, 471-475.
7. Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G (2003). Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotoxicology Research 5, 491-504.
8. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH, Dajas F, Gentry MK, Doctor BP, De Mello FG, Inestrosa NC (1998). Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. Journal of Neuroscience 18, 3213-3223.
9. Alvarez-Arcaya A, Combarros O, Llorca J, Sanchez-Guerra M, Berciano J, Fernandez-Viadero C, Pena N (2000). The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women. Acta Neurologica Scandanavica 102, 350-353.
10. Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L (2001). Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mechanisms of Aging and Development 122, 2057-2062.
11. Andin J, Enz A, Gentsch C, Marcusson J (2004). Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression. Dementia and Geriatric Cognitive Disorders 19, 18-23.
12. Andres C, Beeri R, Friedman A, Lev-Lehman E, Henis S, Timberg R, Shani M, Soreq H (1997). Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin Ibeta gene expression followed by late-onset neuromotor deterioration. Proceedings of the National Academy of Sciences USA 94, 8173-8178.
13. Arendt T, Bruckner MK, Lange M, Bigl V (1992). Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochemistry International 21, 381-396.
14. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH (1986). Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. Journal of Neurochemistry 47, 263-277.
15. Auld DS, Kar S, Quirion R (1998). Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends in Neuroscience 21, 43-49.
16. Ballard CG, Perry EK (2003). The role of butyrylcholinesterase in Alzheimer's disease. In: Giacobini E (Ed.), Butyrylcholinesterase: Its Functions and Inhibitors (pp. 123-134). London: Martin Dunitz.
17. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I (2002). Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 41, 3555-3564.
18. Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003). beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochemical Pharmacology 65, 407-416.
19. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A (2001). Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Research 905, 220-223.
20. Beeri R, Le Novere N, Mervis R, Huberman T, Grauer E, Changeux JP, Soreq H (1997). Enhanced hemicholinium binding and attenuated dendrite branching in cognitively impaired acetylcholinesterase-transgenic mice. Journal of Neurochemistry 69, 2441-2451.
21. Bhanji NH, Gauthier S (2003). Dementia with Lewy Bodies: preliminary observations on cholinesterase inhibitor switching. International Psychogeriatrics 15 (Suppl. 2), 179.
22. Birikh KR, Sklan EH, Shoham S, Soreq H (2003). Interaction of 'readthrough' acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior. Proceedings of the National Academy of Sciences USA 100, 283-288.
23. Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S (2003). Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dementia and Geriatric Cognitive Disorders 15, 79-87.
24. Bon S, Dufourcq J, Leroy J, Cornut I, Massoulie J (2004). The C-terminal peptide of acetylcholinesterase forms an alpha helix that supports homomeric and heteromeric interactions. European Journal of Biochemistry 271, 33-47.
25. Bordier P, Garrigue S, Barold SS, Bressolles N, Lanusse S, Clementy J (2003). Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace 5, 429-431.
26. Brassen S, Adler G (2003). Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial. Pharmacopsychiatry 36, 304-308.
27. Braverman ER, Blum K (2003). P300 (latency) event-related potential: an accurate predictor of memory impairment. Clinical Electroencephalographics 34, 124-139.
28. Brufani M, Filocamo L (2000). Rational design of cholinesterase inhibitors. In: Giacobini E (Ed.), Cholinesterase and Cholinesterase Inhibitors. London: Martin Dunitz.
29. Calvo-Romero JM, Ramos-Salado JL (1999). Symptomatic sinus bradycardia associated with donepezil. Reviews in Neurology 28, 1070-1072.
30. Chedotal A, Umbriace D, Descarries L (1994). Light and electron microscopic immunocytochemical analysis of the neurovascular relationship of choline acetyltransferase and vasoactive intestinal polypeptide nerve terminals in the rat cerebral cortex. Journal of Comparative Neurology 343, 57-71.
31. Chubb I, Goodman S, Smith A (1976). Is acetylcholinesterase secreted from central neurons into the cerebral fluid? Neuroscience 1, 57-62.
32. Cohen O, Erb C, Ginzberg D Pollak Y, Seidman S, Shoham S, Yirmiya R, Soreq H (2002). Neuronal overexpression of 'read through' acetylcholine sterase is associated with antisense-suppressible behavioral impairments. Molecular Psychiatry 7, 874-885.
33. Cuadra G, Summers K, Giacobini E (1994). Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. Journal of Pharmacology and Experimental Therapeutics 270, 277-284.
34. Cummings JL (1990). Introduction. In: Cummings JL (Ed.), Subcortical Dementia (pp. 3-16). New York: Oxford University Press.
35. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B (1998). Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 50, 1214-1221.
36. Darreh-Shori T, Almkvist O, Guan ZZ, Galind AA, Strandberg B, Svensson AL, Soreq H, Hellstrom-Lindahl E, Nordberg A (2002). Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59, 563-572.
37. Darreh-Shori T, Hellstrom-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H, Nordberg A (2004). Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. Journal of Neurochemistry 88, 1102-1113.
38. Darvesh S, Grantham DL, Hopkins DA (1998). Distribution of butyrylcholinesterase in human amygdala and hippocampal formation. Journal of Comparative Neurology 393, 374-390.
39. Darvesh S, Hopkins DA (2003). Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. Journal of Comparative Neurology 463, 25-43.
40. Darvesh S, Hopkins DA, Geula C (2003a). Neurobiology of butyrylcholinesterase. Nature Reviews in Neuroscience 4, 131-138.
41. Darvesh S, Kumar R, Roberts S, Walsh R, Martin E (2001). Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin. Cellular and Molecular Neurobiology 21, 285-296.
42. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, Martin E (2003b). Inhibition of human cholinesterases by drugs used to treat Alzheimer's disease. Alzheimer Disease and Associated Disorders 17, 117-126.
43. Davidsson P, Blennow K, Andreasen N (2001). Differential increase in cerebrospinal fluid acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neuroscience Letters 300, 157-160.
44. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V (1999). Cholinergic markers in elderly patients with early signs of Alzheimer disease. Journal of the American Medical Association 281, 1401-1406.
45. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC (2001). A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 40, 10447-10457.
46. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, et al. (2001). Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron- emission tomography (FDG/PET). Proceedings of the National Academy of Sciences USA 98, 10966-10971.
47. Deijen JB, de Boer H, van der Veen EA (1998). Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology 23, 45-55.
48. Di Angelantonio S, Bernardi G, Mercuri NB (2004). Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones. British Journal of Pharmacology 141, 644-652.
49. Diez JJ, Iglesias P, Selgas R, Bajo MA, Aguilera A (2000). Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis. Clinical Endocrinology (Oxford) 53, 587-593.
50. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, Veach J (2002). Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Progress in Neuro-Psychopharmacology & Biological Psychiatry 26, 705-712.
51. Ebmeier KP, Hunter R, Curran SM, Dougal NJ, Murray CL, Wyper DJ, Patterson J, Hanson MT, Siegfried K, Goodwin GM (1992). Effects of a single dose of acetylcholinesterase inhibitor velnacrine on recognition memory and regional blood flow in Alzheimer's disease. Psychopharmacology 108, 103-109.
52. Emmerling MR, Schwarz RD, Spiegel K (1997). New perspectives on developing muscarinic agonists for treating Alzheimer's disease. ID Research Alert 2, 187-194.
53. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J (1993). Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Progress in Brain Research 98, 431-438.
54. Farlow M (2002). A clinical overview of cholinesterase inhibitors in Alzheimer's disease. International Psychogeriatrics 14 (Suppl. 1), 93-126.
55. Farlow M, Anand R, Messina J, Hartman R, Veach J (2000). A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. European Neurology 44, 236-241.
56. Fisher A, Brandeis R, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z (2002). Impact of muscarinic agonists for successful therapy of Alzheimer's disease. Journal of Neural Transmission 62 (Suppl.), 189-202.
57. Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z (2000). M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Annals of the New York Academy of Science 920, 315-320.
58. Fisher A, Sparks L, Beach TG, Hartmann T, Pittel Z, Haring R, Mestre-Frances N, Bons N, Bar-Ner N, Kliger-Spatz M, et al. (2003). Interaction between cholinergic neurotransmission and underlying Alzheimer's disease pathology: therapeutic implications. In: Iqbal K, Winblad B (Eds.), Alzheimer Disease and Related Disorders: Research Advances (pp. 613-625). Bucharest: Ana Asian International Academy of Aging.
59. Fogelson N, Kogan E, Korczyn AD, Giladi N, Shabtai H, Neufeld MY (2003). Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurologica Scandinavica 107, 252-255.
60. Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S (2000). Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. Journal of Neural Transmission 107, 1201-1212.
61. Frodl-Bauch T, Bottlender R, Hegerl U (1999). Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology 40, 86-94.
62. Geula C, Mesulam M (1995). Cholinesterases and the pathology of Alzheimer's disease. Ahheimer Disease and Associated Disorders 9 (Suppl. 2), 23-28.
63. Giacobini E (2003). Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochemical Research 28, 515-522.
64. Giacobini E (2004). Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacological Research 50, 433-440.
65. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR (2002). Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit. Journal of Neural Transmission 109, 1053-1065.
66. Giacobini E, Zhu XD, Williams E, Sherman KA (1996). The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35, 205-211.
67. Gibson GE (2002). Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease. Free Radicals in Biology and Medicine 32, 1061-1070.
68. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA (1996). Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383, 713-716.
69. Greenwood PM, Sunderland T, Fritz JL, Parasuraman R (2000). Genetics and visual attention: Selective deficits in healthy adult carriers of the ε4 allele of the apolipoprotein E gene. Proceedings of the National Academy of Sciences USA 97, 11661-11666.
70. Greig N, Sambamurti K, Yu Q, Perry TA, Holloway HW, Haberman F, Brossi A, Ingram DK, Lahiri DK (2003). Butyrylcholinesterase: its selective inhibition and relevance to Alzheimer's disease therapy. In: Giacobini E (Ed.), Butyrylcholinesterase: Its Functions and Inhibitors (pp. 69-90). London: Martin Dunitz.
71. Greig N, Utsuki T, Qian-sheng Y, Zhu X, Holloway HW, Perry TA, Lee B, Ingram DK, Lahiri DK (2001). A new therapeutic target in AD treatment: Attention to butyrylcholinesterase. Current Medical Research Opinion 17, 159-165.
72. Grisaru D, Deutsch V, Shapira M, Pick M, Sternfeld M, Melamed-Book N, Kaufer D, Galyam N, Gait MJ, Owen D, et al. (2001). ARP, a peptide derived from the stress-associated acetylcholinesterase variant, has hematopoietic growth promoting activities. Molecular Medicine (New York) 7, 93-105.
73. Grisaru D, Sternfeld M, Eldor A, Glick D, Soreq H (1999). Structural roles of acetylcholinesterase variants in biology and pathology. European Journal of Biochemistry 264, 672-686.
74. Grossberg GT (2003). Cholinesterase inhibitors for the treatment of Alzheimer's disease: Getting on and staying on. Current Therapeutics Research 64, 216-235.
75. Guillozet AL, Shaw P, Mesulam MM (2003). Inhibition of cholinesterases by rivastigmine. Poster presented at the Northwestern University Alzheimer's Day. Chicago, 16 May 2003.
76. Guillozet AL, Smiley JF, Mash DC, Mesulam MM (1997). Butyrylcholinesterase in the life cycle of amyloid plaques. Annals of Neurology 42, 909-918.
77. Hammond EJ, Meador KJ, Aung-Din R, Wilder BJ (1987). Cholinergic modulation of human P3 event-related potentials. Neurology 37, 346-350.
78. Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, Eshhar N, Heldman E (1998). Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. Journal of Neurochemistry 71, 2094-2103.
79. Harkins SW, Taylor JR, Mattay V, Regelson W (1997). Tacrine treatment in Alzheimer's disease enhances cerebral blood flow and mental status and decreases caregiver suffering. Annals of New York Academy of Sciences 826, 472-474.
80. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, Wallace WC (1997). Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Research - Molecular Brain Research 46, 161-168.
81. He W, Barrow CJ (1999). The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 38, 10871-10877.
82. Hellstrom-Lindahl E (2000). Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. European Journal of Pharmacology 393, 255-263.
83. Hinz VC, Kolb J, Schmidt BH (1998). Effects of subchronic administration of metrifonate on cholinergic neurotransmission in rats. Neurochemical Research 23, 931-938.
84. Holmes C, Ballard C, Lehman D, Smith AD, Beaumont H, Day IN, Nadeem Khan M, Lovestone S, McCulley M, Morris CM, et al. (2005). Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. Journal of Neurological and Neurosurgical Psychiatry 76, 640-643.
85. Hooper NM, Turner AJ (2002). The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer's disease. Current Medicinal Chemistry 9, 1107-1119.
86. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996). Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16, 881-891.
87. Isacson O, Seo H, Lin L, Albeck D, Granholm AC (2002). Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends in Neuroscience 25, 79-84.
88. Jhee SS, Shiovitz T, Hartman RD, Messina J, Anand R, Sramek J, Cutler NR (2002). Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clinical Neuropharmacology 25, 122-123.
89. Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO (2002). Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Journal of Clinical Psychopharmacology 22, 615-620.
90. Kalaria RN, Ballard C (1999). Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Disease and Associated Disorders 13 (Suppl. 3), 115-123.
91. Kar S, Issa AM, Seto D, Auld DS, Collier B, Quirion R (1998). Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. Journal of Neurochemistry 70, 2179-2187.
92. Kasa P, Papp H, Kasa Jr. P, Torok I (2000). Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience 101, 89-100.
93. Kaufer D, Friedman A, Seidman S, Soreq H (1998). Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393, 373-377.
94. Kaufer D, Friedman A, Seidman S, Soreq H (1999). Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission. Chemical and Biological Interactions 119-120, 349-60.
95. Kellar KJ, Whitehouse PJ, Martino-Barrows AM, Marcus K, Price DL (1987). Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex. Brain Research 436, 62-68.
96. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, Roth GS, Mattson MP (1996). Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proceedings of the National Academy of Sciences USA 93, 6753-6758.
97. Kievit J, Kuypers HGJM (1977). Organization of the thalamo-cortical connections to the frontal lobe in the rhesus monkey. Experimental Brain Research 29, 299-322.
98. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001). Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. Journal of Biological Chemistry 276, 13541-13546.
99. Kimura A, Okada K, Sato A, Suzuki H (1994). Regional cerebral blood flow in the frontal, parietal and occipital cortices increases independently of systemic arterial pressure during slow walking in conscious rats. Neuroscience Research 20, 309-315.
100. Kirkpatrick CJ, Bittinger F, Nozadze K, Wessler I (2003). Expression and function of the non-neural cholinergic system in endothelial cells. Life Sciences 72, 2111-2116.
101. Krejci E, Thomine S, Boschetti N, Legay C, Sketelj J, Massoulie J (1997). The mammalian gene of acetylcholinesterase-associated collagen. Journal of Biological Chemistry 272, 22840-22847.
102. Kuda T, Shoji M, Arai H, Kawashima S, Saido TC (1997). Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease. Biochemical and Biophysical Research Communications 231, 526-530.
103. Kuhl DE, Minoshima S, Frey KAS, Foster NL, Kilbourn MR, Koeppe RA (2000). Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Annals of Neurology 48, 391-395.
104. Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE (1997). Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochemical and Biophysiological Research Communications 237, 188-191.
105. Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH (2000). Cholinesterase inhibitors, beta amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurologica Scandanavica 102, 60-67.
106. Layer PG, Weikert T, Willbold E (1992). Chicken retinospheroids as developmental and pharmacological in vitro models: acetylcholinesterase is regulated by its own and by butyrylcholinesterase activity. Cell Tissue Research 268, 409-118.
107. Lehmann DJ, Williams J, McBroom J, Smith AD (2001). Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 108, 541-554.
108. Lemstra AW, Eikelenboom P, van Gool WA (2003). The cholinergic deficiency syndrome and its therapeutic implications. Gerontology 49, 55-60.
109. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, Bochynska A (2003). The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. Journal of Neurological Science 216, 119-126.
110. Lu CJ, Tune LE (2003). Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. American Journal of Geriatric Psychiatry 11, 458-461.
111. Maragos WF, Greenamyre JT, Perry JB, Young AB (1987). Glutamate dysfunction in Alzheimer's disease: a hypothesis. Trends in Neuroscience 10, 65-68.
112. Massen P, Froment MT, Bartels CF, Lockridge O (1997). Importance of aspartate-70 in organophosphate inhibition, oxime re-activation and aging of human butyrylcholinesterase. Biochemical Journal 325, 53-61.
113. Massoulie J, Anselmet A, Bon S, Krejci E, Legay C, Morel N, Simon S (1999). The polymorphism of acetylcholinesterase: post-translational processing, quaternary associations and localization. Chemico-Biological Interactions 119-120, 29-42.
114. Masuda Y, Kawamura A (2003). Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. Journal of Cardiovascular Pharmacology 41 (Suppl. 1), S67-S71.
115. Mattson MP (1988). Neurotransmitters in the regulation of neuronal cytoarchitecture. Brain Research 472, 179-212.
116. McCormick DA (1990). Cellular mechanisms of cholinergic control of neocortical and thalamic neuronal excitability. In: Steriade M, Biesold D (Eds.), Brain Cholinergic Systems (pp. 236-264). Oxford: Oxford University Press.
117. McKeith IG, O'Brien KK, Morris CM, Perry EK (2003). Butyrylcholinesterase and dementia with Lewy Bodies: involvement in symptom progression and treatment response. In: Giacobini E (Ed.), Butyrylcholinesterase: Its Functions and Inhibitors (pp. 149-162). London: Martin Dunit.
118. McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA (2003). Cardiovascular effects of donepezil in patients with dementia. Dementia and Geriatric Cognitive Disorders 15, 183-188.
119. Meda L, Baron P, Scarlato G (2001). Glial activation in Alzheimer's disease: the role of A-beta and its associated proteins. Neurobiology of Aging 22, 885-893.
120. Meshorer E, Erb C, Gazit R, Pavlovsky L, Kaufer D, Friedman A, Glick D, Ben-Arie N, Soreq H (2002). Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science 295, 508-512.
121. Mesulam M (1999). Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24, 521-529.
122. Mesulam M (2004). The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learning and Memory 11, 43-49.
123. Mesulam M, Carson K, Price B, Geula C (1992). Cholinesterases in the amyloid angiopathy of Alzheimer's disease. Annals of Neurology 31, 565-569.
124. Mesulam M, Guillozet A, Shaw P, Quinn B (2002a). Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiology of Disease 9, 88-93.
125. Mesulam MM (2000). Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In: Giacobini E (Ed.), Cholinesterases and Cholinesterase Inhibitors (pp. 121-138). London: Martin Dunitz.
126. Mesulam MM (2003). Butyrylcholinesterase in the normal and Alzheimer brain. In: Giacobini E (Ed.), Butyrylcholinesterase: Its Function and Inhibitors. London: Martin Dunitz.
127. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O (2002b). Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neuroscience 110, 627-639.
128. Minger SL, Honer WG, Esiri MM, McDonald B, Keene J, Nicoll JA, Carter J, Hope T, Francis PT (2001). Synaptic pathology in prefrontal cortex is present only with severe dementia in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 60, 929-936.
129. Minthon L, Gustafson L, Dalfelt G, Hagberg B, Nilsson K, Risberg J, Rosen I, Seiving B, Wendt PE (1993). Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 4, 32-42.
130. Moral-Naranjo MT, Cabezas-Herrera J, Vidal CJ, Campoy FJ (2002). Muscular dystrophy with laminin deficiency decreases the content of butyrylcholinesterase tetramers in sciatic nerves of Lama2dy mice. Neuroscience Letters 331, 155-158.
131. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A (2002). Rivastigmine in subcortical vascular dementia: an open 22-month study. Journal of Neurological Science 203-204, 141-146.
132. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Ukmar M, Bava A (2004). Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. International Journal of Clinical Practice 58, 346-353.
133. Mori F, Cuadra G, Giacobini E (1995). Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochemical Research 20, 1081-1088.
134. Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, Saragovi HU, Kordower JH (2000). Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. Journal of Comparative Neurology 427, 19-30.
135. Nachon F, Masson P, Nicolet Y, Lockridge O, Fontecilla-Camps JC (2003). Comparison of the structures of butyrylcholinesterase and acetylcholinesterase. In: Giacobini E (Ed.), Butyrylcholinesterase: Its Functions and Inhibitors (pp. 39-54). London: Martin Dunitz.
136. Nakajima K, Uchida S, Suzuki A, Hotta H, Aikawa Y (2003). The effect of walking on regional blood flow and acetylcholine in the hippocampus in conscious rats. Autonomic Neuroscience: Basic and Clinical 103, 83-92.
137. Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D, Yamaguchi S, Kawabata S, Okada M (1998). Glutamate receptors: brain function and signal transduction. Brain Research and Brain Research Reviews 26, 230-235.
138. Neville LF, Gnatt A, Loewenstein Y, Soreq H (1990). Aspartate-70 to glycine substitution confers resistance to naturally occurring and synthetic anionic-site ligands on in-ovo produced human butyrylcholinesterase. Journal of Neuroscience Research 27, 452-460.
139. Nitsch RM, Rossner S, Albrecht C, Mayhaus M, Enderich J, Schliebs R, Wegner M, Arendt T, von der Kammer H (1998). Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter. Journal of Physiology (Paris) 92, 257-264.
140. Nordberg A (2004). Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. Progress in Brain Research 145, 301-309.
141. Nordberg A, Amberla K, Shigeta M, Lundqvist H, Viitanen M, Hellstrom-Lindahl E, Johansson M, Andersson J, Hartvig P, Lilja A, et al. (1998). Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Disease and Associated Disorders 12, 228-237.
142. Nordberg A, Hellström-Lindahl E, Almkvist O, Meurling L (1999). Activity of acetylcholinesterase in CSF increases in Alzheimer's patients after treatment with tacrine. Alzheimers Report 2, 347-352.
143. Nordberg A, Stefanova E, Darreh-Shori T, Wall A (2003). Butyrylcholinesterase: studies with brain imaging. In: Giacobini E (Ed.), Butyrylcholinesterase: Its Functions and Inhibitors (pp. 91-100). London: Martin Dunitz.
144. Obermayr RP, Mayerhofer L, Knechtelsdorfer M, Tragl KH, Geyer G (2003). The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease. Gerontology 49, 191-195.
145. O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien JT, Swan AG, Farbairn AF, Wesnes K, et al. (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13, 231-239.
146. Ogawa M, Magata Y, Ouchi Y, Fukuyama H, Yamauchi H, Kimura J, Yonekura Y, Konishi J (1994). Scopolamine abolishes cerebral blood flow response to somatosensory stimulation in anaesthetized cats: PET study. Brain Research 650, 249-252.
147. Opazo C, Inestrosa NC (1998). Crosslinking of amyloid-beta peptide to brain acetylcholinesterase. Molecular Chemical Neuropathology 33, 39-49.
148. Ordentlich A, Barak D, Kronman C, Ariel N, Sega Y, Velan B, Shafferman A (1995). Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase. Journal of Biological Chemistry 270, 2082-2091.
149. O'Shea JJ, Ma A, Lipsky P (2002). Cytokines and autoimmunity. Nature Reviews Immunology 2, 37-45.
150. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V (2002). Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurological Science 23 (Suppl. 2), 95-96.
151. Perrier AL, Massoulie J, Krejci E (2002). PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 33, 275-285.
152. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH (2003a). Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Annals of Neurology 54, 235-238.
153. Perry E, McKeith I, Ballard C (2003b). Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 60, 1852-1853.
154. Perry EK, Perry RH, Blessed G, Tomlinson BE (1978). Changes in brain cholinesterase in senile dementia of Alzheimer's type. Neuropathology and Applied Neurobiology 4, 273-277.
155. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thai LJ (Alzheimer's Disease Cooperative Study Group) (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 352, 2379-2388.
156. Pettigrew LC, Bieber F, Lettieri J, Wermeling DP, Schmitt FA, Tikhtman AJ, Ashford JW, Smith CD, Wekstein DR, Markesbery WR, et al. (1998). Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. Journal of Clinical Pharmacology 38, 236-245.
157. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, Bartolini M, Andrisano V, Valenti P, Recanatini M (2003). 3-(4-[[Benzyl(methyl)amino]methyl] phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. Journal of Medical Chemistry 46, 2279-2282.
158. Planel E, Sun X, Takashima A (2002). Role of GSK-3 in Alzheimer's disease pathology. Drug Development Research 56, 491-110.
159. Poirier J (2002). Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. International Journal of Clinical Practice 127 (Suppl.), 6-19.
160. Polich J (1996). Meta-analysis of P300 normative aging studies. Psychophysiology 33, 334-353.
161. Polich J, Ladish C, Bloom FE (1990). P300 assessment of early Alzheimer disease. Electroencephalographics and Clinical Neurophysiology 77, 179-189.
162. Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH (2001). Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. International Journal of Neuropsychopharmacology 4, 223-230.
163. Prince RJ, Pennington RA, Sine SM (2002). Mechanism of tacrine block at adult human muscle nicotinic acetylcholine receptors. Journal of General Physiology 120, 369-393.
164. Radic Z, Pickering NA, Vellom DC, Camp SP, Taylor SP (1993). Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 32, 12074-12084.
165. Rakonczay Z (2003). Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biologica Hungarica 54, 183-189.
166. Ramirez-Exposito MJ, Robert-Baudouy J, Mayas MD, Garcia MJ, Ramirez M, Martinez-Martos JM (2001). Acetylcholinesterase inhibitor SDZ ENA 713 (Rivastigmine) increases brain pyrrolidone carboxyl peptidase activity. European Neuropsychopharmacology 11, 381-383.
167. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D (2004). Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. Journal of Neuroimmunology 148, 162-171.
168. Rehman HU, Masson EA (2001). Neuroendocrinology of ageing. Age and Ageing 30, 279-287.
169. Rinne JO, Kaasinen V, Jarvenpaa T, Nagren K, Roivainen A, Yu M, Oikonen V, Kurki T (2003). Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry 74, 113-115.
170. Rinne JO, Virta J, Nagren K, Jarvenpaa T, Roivainen A, Oikonen V, Kurki T (2004). Effects of rivastigmine and donepezil on brain butyrylcholinesterase activity in patients with Alzheimer's disease. Poster presented at 8th International Springfield Symposium on Advances in Alzheimer Therapy, Montreal.
171. Rogers J, Morrison JH (1985). Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. Journal of Neuroscience 5, 2801-2808.
172. Roher AE, Kuo YM, Potter PE (2000). Cortical cholinergic denervation elicits vascular A beta deposition. Annals of the New York Academy of Science 903, 374-386.
173. Sadoshima S, Ibayashi S, Fujii K, Nagao T, Sugimori H, Fujishima M (1995). Inhibition of acetylcholinesterase modulates the autoregulation of cerebral blood flow and attenuates ischaemic brain metabolism in hypertensive rats. Journal of Cerebral Blood Flow and Metabolism 15, 845-851.
174. Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A (1996). Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. Journal of Neurochemistry 66, 877-880.
175. Saez-Valero J, de Ceballos ML, Small DH, de Felipe C (2002). Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide. Neuroscience Letters 325, 199-202.
176. Saido TC, Iwatsubo T, Mann DMA, Shimada H, Ihara Y, Kawashima S (1995). Dominant and differential deposition of distinct b-amyloid peptide species, AbN3(pE), in senile plaques. Neuron 14, 457-466.
177. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S (Donepezil 401 Study Group) (2004). Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63, 651-657.
178. 11C]methionine accumulation in probable Alzheimer's disease using positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 16, 309-408.
179. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A (2000). Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurologica Scandanavica 176 (Suppl.), 68-73.
180. Sarter M, Bruno JP (1997). Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis. Brain Research Reviews 23, 28-46.
181. Sassin I, Schultz C, Thal DR, Rub U, Arai K, Braak E, Braak H (2000). Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathologica (Berlin) 100, 259-269.
182. Schneider-Rivas S, Rivas-Arancibia S, Vazquez-Pereyra F, Vazquez-Sandoval R, Borgonio-Perez G (1995). Modulation of long-term memory and extinction responses induced by growth hormone (GH) and growth hormone releasing hormone (GHRH) in rats. Life Sciences 56, 433-441.
183. Schubert P, Ogata T, Marchini C, Ferroni S (2001). Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target? Mechanisms of Ageing and Development 123, 47-57.
184. Selden NR, Gitelmen DR, Salamon-Muryayma N, Parrish TB, Mesulam MM (1998). Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121, 2249-2257.
185. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David JP, Vanmechelen E, Sergheraert C, Delacourte A (2003). Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. Journal of Neurochemistry 85, 1581-1591.
186. Shapira M, Grant A, Korner M, Soreq H (2000). Genomic and transcriptional characterization of the human ACHE locus: complex involvement with acquired and inherited diseases. Israeli Medical Association Journal 2, 470-473.
187. Shepherd G, Klein-Schwartz W, Edwards R (1999). Donepezil overdose: a tenfold dosing error. Annals of Pharmacotherapy 33, 812-815.
188. Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T, Tanada S, Irie T (2001). Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 56, 408-410.
189. Shohami E, Kaufer D, Chen Y, Seidman S, Cohen O, Ginzberg D, Melamed-Book N, Yirmiya R, Soreq H (2000). Antisense prevention of neuronal damages following head injury in mice. Journal of Molecular Medicine 78, 228-236.
190. Siek GC, Katz LS, Fishman EB, Korosi TS, Marquis JK (1990). Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biological Psychiatry 27, 573-580.
191. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, et al. (2001). Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. Journal of the American Medical Association 286, 2120-2127.
192. Singh S, Dudley C (2003). Discontinuation syndrome following donepezil cessation. International Journal of Geriatric Psychiatry 18, 282-284.
193. Small DH, Mok SS, Bornstein JC (2001). Alzheimer's disease and Abeta toxicity: from top to bottom. Nature Reviews in Neuroscience 2, 595-598.
194. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, et al. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences USA 97, 6037-6042.
195. Soreq H, Glick D (2000). Novel roles for cholinesterases in stress and inhibitor responses. In: Giacobini E (Ed.), Cholinesterases and Cholinesterase Inhibitors (pp. 47-62). London: Martin Dunitz.
196. Soreq H, Seidman S (2001). Acetylcholinesterase - new roles for an old actor. Neuroscience 2, 294-302.
197. Soreq H, Zakut H (1993). Human Cholinesterases and Anticholinesterases. New York: Academic Press.
198. Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G (2003). Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Journal of Clinical Psychiatry 64, 466-472.
199. Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A (2003). Cerebral glucose metabolism, cerebrospinal fluid-β-amyloid 1-42 (CSF Aβ 42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine-treated Alzheimer's disease in patients. Neuroscience Letters 338, 159-163.
200. Sternfeld M, Shoham S, Klein O, Flores-Flores C, Evron T, Idelson GH, Kitsberg D, Patrick JW, Soreq H (2000). Excess 'read-through' acetylcholinesterase attenuates but the 'synaptic' variant intensifies neurodeterioration correlates. Proceedings of the National Academy of Sciences USA 97, 8647-8652.
201. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I (1991). Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253, 872-879.
202. Swaab DF, Hofman MA, Lucassen PJ, Salehi A, Uylings HB (1994). Neuronal atrophy, not cell death, is the main hallmark of Alzheimer's disease. Neurobiology of Aging 15, 369-371.
203. Tanaka K, Mizukawa K, Ogawa N, Mori A (1995). Post-ischaemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus. Neurochemical Research 20, 663-667.
204. Tanaka K, Ogawa N, Mizukawa K, Asanuma M, Kondo Y, Nishibayashi S, Mori A (1994). Acetylcholinesterase inhibitor ENA-713 protects against ischaemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia. Neurochemical Research 19, 117-122.
205. Taylor P, Radic Z (1994). The cholinesterases: from genes to proteins. Annual Review of Pharmacological Toxicology 34, 281-320.
206. Thomas A, Iacono D, Bonanni L, D'Andreamatteo G, Onofrj M (2001). Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clinical Neuropharmacology 24, 31-42.
207. Thomsen L, Kewitz H (1990). Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sciences 46, 1553-1558.
208. Toda N, Okamura T (2003). The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacological Reviews 55, 271-324.
209. Tomkins O, Kaufer D, Korn A, Shelef I, Golan H, Reichenthal E, Soreq H, Friedman A (2001). Frequent blood-brain barrier disruption in the human cerebral cortex. Cellular and Molecular Neurobiology 21, 675-691.
210. Tong XK, Hamel E (1999). Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 92, 163-175.
211. Trabace L, Cassano T, Cagiano R, Tattoli M, Pietra C, Steardo L, Kendrick KM, Cuomo V (2001). Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. Brain Research 910, 182-186.
212. Tsujimoto S, Sakaki T, Morimoto T, Tominaga M (1993). The effect of acetylcholinesterase inhibitor (SDZ ENA 713) for r-CBF and focal cerebral ischemia. Acta Neurochirurgia (Wien) 124, 127-131.
213. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ (2002). Alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochemical and Biophysical Research Communications 299, 373-376.
214. Utsuki T, Shoaib M, Holloway HW, Ingram DK, Wallace WC, Haroutunian V, Sambamurti K, Lahiri DK, Greig NH (2002). Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. Journal of Alzheimers Disease 4, 405-415.
215. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD (2002). Cholinesterase inhibition increases regional cerebral blood flow and restores function in Alzheimer's disease. Neuroreport 13, 83-87.
216. Wallace WC, Bragin V, Robakis NK, Sambamurti K, VanderPutten D, Merril CR, Davis KL, Santucci AC, Haroutunian V (1991). Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Research and Molecular Brain Research 10, 173-178.
217. Wallace WC, Lieberburg I, Schenk D, Vigo-Pelfrey C, Davis KL, Haroutunian V (1995). Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. Journal of Neurosciences 15, 4896-4905.
218. Warpman U, Zhang X, Nordberg A (1996). Effect of tacrine on in vivo release of dopamine and its metabolites in the striatum of freely moving rats. Journal of Pharmacology and Experimental Therapeutics 277, 917-922.
219. Werber EA, Gandelman-Marton R, Klein C, Rabey JM (2003). The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients. Journal of Neural Transmission 110, 659-669.
220. Whyte KA, Greenfield SA (2003). Effects of acetylcholinesterase and butyrylcholinesterase on cell survival, neurite outgrowth, and voltage-dependent calcium currents of embryonic ventral mesencephalic neurons. Experimental Neurology 184, 496-509.
221. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD (2003). Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology 61, 479-486.
222. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS (2002). A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. International Journal of Clinical Practice 56, 441-446.
223. Wright CI, Geula C, Mesulam MM (1993). Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles and patterns on selective vulnerability. Annals of Neurology 34, 373-384.
224. Zhang L, Zhou F-M, Dani JA (2004). Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Molecular Pharmacology 66, 538-544.
225. Zhao Q, Tang XC (2002). Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. European Journal of Pharmacology 455, 101-107.